Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease…

Overview of attention for article published in Endocrine Practice, September 2025

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

facebook: 1 Facebook page

Readers on

mendeley: 8 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 8,805 followers.

A study coauthored by Dr. Guillermo E. Umpierrez in 388K+ adults with type 2 diabetes found: SGLT2i ↓ pancreatitis risk vs DPP-4i, sulfonylureas ↑ risk vs GLP-1RA & SGLT2i, and GLP-1RA ↓ pancreatic cancer risk vs DPP-4i https://t.co/Oe45iborWi

RT @lgoodbu: Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylure…

Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk - ScienceDirect https://t.co/oQiCPgHVd0

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.